Kashanchi F, Araujo J, Doniger J, Muralidhar S, Hoch R, Khleif S, Mendelson E, Thompson J, Azumi N, Brady J N, Luppi M, Torelli G, Rosenthal L J
Laboratory of Molecular Virology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Oncogene. 1997 Jan 23;14(3):359-67. doi: 10.1038/sj.onc.1200840.
The 357 amino acid open reading frame 1 (ORF-1), also designated DR7, within the SalI-L fragment of human herpesvirus 6 (HHV-6) exhibited transactivation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) promoter and increased HIV-1 replication (Kashanchi et al., Virology, 201, 95-106, 1994). In the current study, the SalI-L transforming region was localized to the SalI-L-SH subfragment. Several ORFs identified in SalI-L-SH by sequence analysis were cloned into a selectable mammalian expression vector, pBK-CMV. Only pBK/ORF1 transformed NIH3T3 cells. Furthermore, cells expressing ORF-1 protein produced fibrosarcomas when injected into nude mice, whereas control cells, expressing either no ORF-1 protein or C-terminal truncated (after residue 172) ORF-1 protein, were not tumorigenic. Western blot analysis of proteins extracted from the tumors revealed ORF-1 protein. Additional studies indicated that ORF-1 was expressed in HHV-6-infected human T-cells by 18 h. Co-immunoprecipitation experiments showed that ORF-1 protein bound to tumor suppressor protein p53, and the ORF-1 binding domain on p53 was located between residues 28 and 187 of p53, overlapping with the specific DNA binding domain. Functional studies showed that p53-activated transcription was inhibited in ORF-1, but not in truncated ORF-1, expressing cells. Importantly, the truncated ORF-1 mutant also failed to cause transformation. Analysis of several human tumors by PCR revealed ORF-1 DNA sequences in some angioimmunoblastic lymphadenopathies, Hodgkin's and non-Hodgkin's lymphomas and glioblastomas. The detection of ORF-1 sequences in human tumors, while not proof per se, is a prerequisite for establishing its role in tumor development. Taken together, the results demonstrate that ORF-1 is an HHV-6 oncogene that binds to and affects p53. The identification of both transforming and transactivating activities within ORF-1 is a characteristic of other viral oncogenes and is the first reported for HHV-6.
人类疱疹病毒6型(HHV - 6)的SalI - L片段中的357个氨基酸的开放阅读框1(ORF - 1),也被称为DR7,可激活人类免疫缺陷病毒1型(HIV - 1)长末端重复序列(LTR)启动子,并增加HIV - 1的复制(卡尚奇等人,《病毒学》,201卷,95 - 106页,1994年)。在本研究中,SalI - L转化区域定位于SalI - L - SH亚片段。通过序列分析在SalI - L - SH中鉴定出的几个开放阅读框被克隆到一个可选择的哺乳动物表达载体pBK - CMV中。只有pBK/ORF1能转化NIH3T3细胞。此外,表达ORF - 1蛋白的细胞注射到裸鼠体内时会产生纤维肉瘤,而不表达ORF - 1蛋白或表达C末端截短(在第172位残基之后)的ORF - 1蛋白的对照细胞则没有致瘤性。对从肿瘤中提取的蛋白质进行的蛋白质印迹分析显示存在ORF - 1蛋白。进一步的研究表明,在HHV - 6感染的人类T细胞中,ORF - 1在18小时时开始表达。免疫共沉淀实验表明,ORF - 1蛋白与肿瘤抑制蛋白p53结合,且p53上的ORF - 1结合结构域位于p53的第28位和第187位残基之间,与特定的DNA结合结构域重叠。功能研究表明,在表达ORF - 1的细胞中p53激活的转录受到抑制,但在表达截短的ORF - 1的细胞中则没有。重要的是,截短的ORF - 1突变体也未能引起转化。通过聚合酶链反应(PCR)对几种人类肿瘤进行分析,在一些血管免疫母细胞性淋巴结病、霍奇金淋巴瘤和非霍奇金淋巴瘤以及胶质母细胞瘤中发现了ORF - 1的DNA序列。在人类肿瘤中检测到ORF - 1序列,虽然本身并非确凿证据,但却是确定其在肿瘤发生中作用的前提条件。综上所述,结果表明ORF - 1是一种HHV - 6癌基因,它能与p53结合并影响p53。ORF - 1中同时具有转化和反式激活活性是其他病毒癌基因的一个特征,也是首次在HHV - 6中报道。